Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled in 4 early-phase trials were pooled. Rates of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Roberts, Andrew W., Ma, Shuo, Kipps, Thomas J., Coutre, Steven E., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Byrd, John C., Humphrey, Kathryn, Zhou, Lang, Chyla, Brenda, Nielsen, Jacqueline, Potluri, Jalaja, Kim, Su Young, Verdugo, Maria, Stilgenbauer, Stephan, Wierda, William G., Seymour, John F.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2019
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624969/
https://ncbi.nlm.nih.gov/pubmed/31023700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2018882555
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items